5 December 2017 - Deborah Wilkes
Archived
Alliance Pharma is set to boost its consumer healthcare portfolio by acquiring worldwide rights to the head-lice treatment Vamousse from TyraTech and TYRU in a deal worth up to USD17.5 million.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.